Asthma
Conditions
Keywords
Eosinophilic inflammation, Mepolizumab, Asthma
Brief summary
Mepolizumab, a humanized monoclonal antibody, has been developed as an add-on treatment for subjects with severe asthma with eosinophilic inflammation. Current asthma treatment guidelines offer minimal options for the severe asthmatic subjects on intensive therapy with frequent exacerbations. There is a significant unmet medical need to provide better treatment options for this segment of the asthma population. Thus, this study is designed to evaluate the efficacy and safety of mepolizumab in Chinese severe asthmatic subjects with eosinophilic inflammation. A total number of 300 subjects will be randomized in 1:1 ratio to receive either mepolizumab or placebo along with existing standard of care therapy. The maximum study duration will be 56 weeks.
Interventions
DRUGMepolizumab 100 milligrams
Mepolizumab will be given as a lyophilized cake in sterile vials for individual use. The vial will be reconstituted with Sterile Water for Injection, just prior to use.
DRUGPlacebo
Placebo will be given as 0.9 percent sodium chloride solution.
DRUGSalbutamol
Salbutamol MDI will be given as a rescue medication to be used on an as needed basis in this study.
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Masking description
This will be a double blind study. Subjects and investigator will be masked.
Intervention model description
Eligible subjects will be randomized in 1:1 ratio to receive either mepolizumab or placebo along with existing standard of care therapy during the treatment period.
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects who will be able to give written informed consent prior to participation in the study, which will include the ability to comply with the requirements and restrictions listed in the consent form. Subjects must be able to read, comprehend, and write at a level sufficient to complete study related materials. * Subjects with at least 12 years of age at Visit 0 and a minimum weight of 40 kilograms. * Persistent airflow obstruction as indicated by: For subjects \>=18 years of age at visit 1, a pre-bronchodilator FEV1 \<80 percent predicted (National Health and Nutrition Examination Survey \[NHANES\] III).;For subjects 12 to 17 years of age at Visit 1: A pre-bronchodilator FEV1 \<90 percent predicted (NHANES III) recorded at Visit 1 or FEV1: Forced vital capacity (FVC) ratio \<0.8 recorded at Visit 1. * Prior documentation of eosinophilic asthma or high likelihood of eosinophilic asthma as per Randomization Criteria 1 (Documented peripheral blood eosinophil count of \>=300 cells per microliters that is related to asthma in the past 12 months prior to Visit 1 or a peripheral blood eosinophil count of \>=150 cells per microliters at Visit 1 that is related to asthma). * Regular treatment with high dose inhaled corticosteroid (ICS) in the 12 months prior to Visit 1, of which at least 9 months accumulated documented is required, the 3 months prior to Visit 1 is mandatory. With or without maintenance oral corticosteroids (OCS). ICS dose must be \>=500 microgram per day fluticasone propionate (FP) or equivalent daily (for ICS/long-acting beta-2-agonists combination preparations, Seretide 50/250 micrograms twice daily and above or equivalent will meet this ICS criteria). (Maintenance OCS is defined as a prescribed regimen of a minimum average daily dose of prednisone 5 milligrams \[or equivalent\]). * Current treatment with an additional controller medication, besides ICS, for at least 3 months. (Example given \[e.g.\], long-acting beta-2-agonist, leukotriene receptor antagonist \[LTRA\], or theophylline). * Previously confirmed history of two or more exacerbations requiring treatment with systemic corticosteroid (intramuscular \[IM\], intravenous, or oral), in the 12 months prior to Visit 1, despite the use of high-dose ICS. For subjects receiving maintenance corticosteroid, the corticosteroid treatment for the exacerbations must have been a two-fold increase or greater in the dose for at least 3 days is required. * A female subject is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of childbearing potential (WOCBP) OR is a WOCBP and using a contraceptive method that is highly effective, with a failure rate of \<1 percent, during the intervention period and for at least 4 months after the last dose of study intervention. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention. A WOCBP must have a negative highly sensitive pregnancy test before the first dose of study intervention. If urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the subject must be excluded from participation if the serum pregnancy result is positive. Follicle-stimulating hormone will be assessed to confirm child-bearing status as needed in non WOCBP.
Exclusion criteria
* Current smokers or former smokers with a smoking history of \>=10 pack years (number of pack years = (number of cigarettes per day/20) x number of years smoked). A former smoker is defined as a subject who quit smoking at least 6 months prior to Visit 1. * Presence of a known pre-existing, clinically significant lung condition other than asthma, in the opinion of the Investigator, is expected to affect the subject's asthma status or the subject's ability to participate in the study. This includes current bacterial or viral infection of the upper or lower respiratory tract, bronchiectasis, pulmonary fibrosis, bronchopulmonary aspergillosis, or diagnoses of emphysema or chronic bronchitis (chronic obstructive pulmonary disease other than asthma) or a history of lung cancer. Clinically Significant is defined as any disease/condition that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study. * A chest X-ray that reveals evidence of clinically significant abnormalities not believed to be due to the presence of asthma. * Bronchial Thermoplasty and Radiotherapy are excluded for 12 months prior to visit 1 and throughout the study. * A current malignancy or previous history of cancer in remission for less than 12 months prior to screening (Subjects that had localized carcinoma of the skin which was resected for cure will not be excluded). * Current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice or cirrhosis. Subjects with ALT \>2 times Upper Limit of Normal (ULN), bilirubin \>1.5 times ULN (isolated bilirubin \>1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35 percent) * Subjects who have known, pre-existing severe or clinically significant cardiovascular disease uncontrolled with standard treatment. Including but not limited to: known ejection fraction of \<30 percent or severe heart failure meeting New York Heart Association Class IV classification or hospitalized in the 12 months prior to Visit 1 for severe heart failure meeting New York Heart Association Class III or angina diagnosed less than 3 months prior to Visit 1 or at Visit 1. * QT interval corrected by Fridericia's formula (QTc\[F\]) \>450 milliseconds (msec) or QTc(F) \>480 msec for subjects with Bundle Branch Block at Visit 1 is exclusive. * Subjects who have known, pre-existing, clinically significant endocrine, autoimmune, metabolic, neurological, renal, gastrointestinal, hepatic, hematological or any other system abnormalities that are uncontrolled with standard treatment. Current malignancy except for basal and squamous skin cancer. * Subjects with other conditions that could lead to elevated eosinophils such as Hypereosiniophilic Syndromes, including Churg-Strauss Syndrome, or Eosinophilic Esophagitis. * Subjects with a known, pre-existing parasitic infestation within 6 months prior to Visit 1 are also excluded. * A history (or suspected history) of alcohol misuse or substance abuse within 2 years prior to Visit 1. Alcohol abuse is defined as: an average weekly intake of greater than 21 units or an average daily intake of greater than three units (males), or defined as an average weekly intake of greater than 14 units or an average daily intake of greater than two units (females). One unit was equivalent to a half-pint (220 milliliters) of beer or one (25 milliliters) measure of spirits or one glass (125 milliliters) of wine. * A known immunodeficiency (e.g., human immunodeficiency virus - HIV), other than that explained by the use of corticosteroids taken as therapy for asthma. * Subjects who have received omalizumab (Xolair) within 130 days of Visit 1. * Subjects who have received any monoclonal antibodies (other than Xolair) to treat inflammatory disease within 5 half-lives of Visit 1. * Use of herbals within 7 days prior to visit 1, unless in the opinion of the Investigator and GlaxoSmithKline (GSK) Medical Monitor the medication will not interfere with the study procedures or compromise subject safety. * Subjects who have received treatment with an investigational drug within the past 30 days or five terminal phase half-lives of the drug whichever is longer, prior to visit 1 (this also includes investigational formulations of marketed products). * Subjects with allergy/intolerance to a monoclonal antibody or biologic. * Subjects who are pregnant or breastfeeding. Subjects should not be enrolled if they plan to become pregnant during the time of study participation. * Subjects who have known evidence of lack of adherence to controller medications and/or ability to follow physician's recommendations. * Previously participated in any study with mepolizumab and received investigational product (including placebo). * A subject will not be eligible for this study if he/she is an immediate family member of the participating investigator, sub-investigator, study coordinator, or employee of the participating investigator. * Subjects with a history of psychiatric disease, intellectual deficiency, poor motivation or other conditions that will limit the validity of informed consent to participate in the study. Re-screening of subjects will be allowed only upon approval by the medical monitor.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of Clinically Significant Exacerbations of Asthma | Up to Week 52 | Clinically significant exacerbation is defined as worsening of asthma which requires use of systemic corticosteroids and/or hospitalizations and/or Emergency Department (ED) visits. Analysis of the number of exacerbations was performed using a negative binomial model with covariates of treatment group, baseline maintenance Oral Corticosteroids (OCS) therapy (OCS vs. no OCS), region, exacerbations in the year prior to the study (as an ordinal variable) and baseline % predicted Forced Expiratory Volume in 1 second (FEV1), and with logarithm of time on treatment as an offset variable. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Clinically Significant Abnormal 12-Lead Electrocardiogram (ECG) Findings | Up to Week 52 | 12-Lead electrocardiogram (ECG) measurements were obtained after the participants had rested in the supine position for 5 minutes. Clinically significant abnormal findings are based on the judgement of the investigator. |
| Number of Participants With Positive Anti-Mepolizumab Antibody | Up to Week 52 | Blood samples were collected for detection of binding and neutralizing anti-mepolizumab antibodies. Samples with a positive screening result continued for confirmation analysis. Samples with a positive confirmation analysis were considered positive for mepolizumab Anti-drug antibody (ADA). |
| Percent Probability of First Clinically Significant Exacerbations at Week 16, Week 32, and Week 52 | Week 16, 32 and 52 | Clinically significant exacerbation is defined as worsening of asthma which requires use of systemic corticosteroids and/or hospitalizations and/or Emergency Department (ED) visits. Analysis of the number of exacerbations was performed using a negative binomial model with covariates of treatment group, baseline maintenance Oral Corticosteroids (OCS) therapy (OCS vs. no OCS), region, exacerbations in the year prior to the study (as an ordinal variable) and baseline % predicted Forced Expiratory Volume in 1 second (FEV1), and with logarithm of time on treatment as an offset variable. Time to first clinically significant exacerbation was analyzed using Kaplan-Meier estimates and expressed in terms of probability. |
| Mean Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) at Week 52 | Baseline and Week 52 | The SGRQ Questionnaire is a well-established, self-completed tool, with 50 questions comprising three domains: Symptoms, Activity, and Impacts scores (each ranging from 0 to 100; where higher score indicates worst outcome). SGRQ total score was calculated by summing weights from all positive items, divided by sum of weights for all items in SGRQ questionnaire and multiplying by 100. The SGRQ total score ranges from 0 to 100, with 0 implying the best possible health status and 100 implying worst possible health status. Analysis was performed using mixed model repeated measures with covariates of baseline, baseline maintenance OCS therapy (OCS vs. no OCS), exacerbations in the year prior to the study (as an ordinal variable), baseline % predicted FEV1, treatment and visit, plus interaction terms for visit by baseline and visit by treatment group. |
| Number of Participants With Clinically Significant Exacerbations Requiring Hospitalization (Including Intubation and Admittance to an Intensive Care Unit [ICU]) or Emergency Department (ED) Visits | Up to Week 52 | An exacerbation is defined as worsening of asthma requiring the use of systemic corticosteroids and/or emergency department visit, or hospitalization. The number of exacerbations requiring hospitalization including incubation and admittance to an Intensive care unit (ICU) or ED visits were evaluated. Analysis of number of exacerbations was performed using a negative binomial model with covariates of treatment group, baseline maintenance OCS therapy (OCS vs. no OCS), exacerbations in the year prior to the study (as an ordinal variable) and baseline % predicted FEV1, and with logarithm of time on treatment as an offset variable. The data for participants with 0, 1, 2 and 3 exacerbations requiring hospitalization (including intubation and admittance to an ICU) or ED visits are summarized. |
| Number of Participants With Clinically Significant Exacerbations Requiring Hospitalization | Up to Week 52 | An exacerbation is defined as worsening of asthma requiring the use of systemic corticosteroids and/or emergency department visit, or hospitalization. Analysis of number of exacerbations was performed using a negative binomial model with covariates of treatment group, baseline maintenance OCS therapy (OCS vs. no OCS), exacerbations in the year prior to the study (as an ordinal variable) and baseline % predicted FEV1, and with logarithm of time on treatment as an offset variable. The summary data for participants with 0, 1, 2 and 3 exacerbations requiring hospitalization are summarized. |
| Mean Change From Baseline in Clinic Prebronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 52 | Baseline and Week 52 | FEV1 is the volume of air that can be forced out in one second after taking a deep breath. Prebronchodilator FEV1 were measured via spirometer at Baseline and Week 52. Analysis was performed using mixed model repeated measures with covariates of baseline, baseline maintenance OCS therapy (OCS vs. no OCS), exacerbations in the year prior to the study (as an ordinal variable), treatment and visit, plus interaction terms for visit by baseline and visit by treatment group. |
| Number of Participants With Adverse Events (AEs) Including Systemic (i.e., Allergic [Type I Hypersensitivity] and Other Systemic) and Injection Site Reactions | Up to Week 52 | AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Systemic reactions and local injection site reactions are adverse events of special interest (AESIs). |
| Change From Baseline in Platelets Count | Baseline and Week 52 | Blood samples was collected for the assessment of change from baseline in hematology parameter Platelets count. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. |
| Change From Baseline in Erythrocytes Count | Baseline and Week 52 | Blood samples was collected for the assessment of change from baseline in hematology parameter Erythrocytes count. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. |
| Change From Baseline in Hematocrit | Baseline and Week 52 | Blood samples was collected for the assessment of change from baseline in hematology parameter Hematocrit. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. |
| Percent Change From Baseline in Mean White Blood Cell (WBC) Count With Differential (Neutrophils, Lymphocytes, Monocytes. Eosinophils and Basophils) | Baseline and Week 52 | Blood samples was collected for the assessment of change from baseline in WBC) count with differential (neutrophils, lymphocytes, monocytes. eosinophils and basophils). Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. |
| Change From Baseline in Alkaline Phosphatase | Baseline and Week 52 | Blood samples was collected for the assessment of change from baseline in clinical parameter Alkaline Phosphatase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. |
| Change From Baseline in Alanine Aminotransferase and Aspartate Aminotransferase | Baseline and Week 52 | Blood samples was collected for the assessment of change from baseline in clinical parameter Alanine Aminotransferase, Aspartate Aminotransferase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. |
| Change From Baseline in Albumin and Total Protein | Baseline and Week 52 | Blood samples was collected for the assessment of change from baseline in clinical parameter albumin, total protein. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. |
| Change From Baseline in Clinical Chemistry Parameters | Baseline and Week 52 | Blood samples was collected for the assessment of change from baseline in clinical parameter including total and direct bilirubin, creatinine, glucose, calcium, sodium, potassium, urea. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value. |
| Mean Change From Baseline in Pulse Rate | Baseline and Week 52 | Pulse rate measurement were measured in a sitting position after 5 minutes rest. |
| Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | Baseline and Week 52 | SBP and DBP were measured in a sitting position after 5 minutes rest. The normal range for SBP is 90-140 mmHg and DBP is 60-90 millimeters of mercury (mmHg). |
Countries
China
Participant flow
Pre-assignment details
Approximately 371 participants with severe asthma and eosinophilic inflammation who meet the protocol defined inclusion criteria were screened. Off these, 300 participants were randomized in 1:1 ratio to mepolizumab: placebo arms. 149 participants in the mepolizumab treatment group and 151 participants in the placebo treatment group.
Participants by arm
| Arm | Count |
|---|---|
| Mepolizumab 100mg Participants received 100mg of Mepolizumab subcutaneously every 4 weeks during the total treatment period of 52 weeks in addition to their baseline Standard of Care (SOC) treatment for asthma. Participants received salbutamol as a rescue medication on need basis. | 149 |
| Placebo Participants received placebo matching to Mepolizumab administered subcutaneously every 4 weeks during the total treatment period of 52 weeks in addition to their baseline SOC treatment for asthma. Participants received salbutamol as a rescue medication on need basis. | 151 |
| Total | 300 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 0 | 6 |
| Overall Study | Lack of Efficacy | 0 | 5 |
| Overall Study | Lost to Follow-up | 0 | 1 |
| Overall Study | Physician Decision | 1 | 0 |
| Overall Study | Protocol Violation | 0 | 1 |
| Overall Study | Withdrawal by Subject | 3 | 0 |
Baseline characteristics
| Characteristic | Mepolizumab 100mg | Placebo | Total |
|---|---|---|---|
| Age, Continuous | 50.8 Years STANDARD_DEVIATION 12.59 | 53.7 Years STANDARD_DEVIATION 13.59 | 52.2 Years STANDARD_DEVIATION 13.16 |
| Race/Ethnicity, Customized Asian - East Asian Heritage | 149 Participants | 151 Participants | 300 Participants |
| Sex: Female, Male Female | 81 Participants | 83 Participants | 164 Participants |
| Sex: Female, Male Male | 68 Participants | 68 Participants | 136 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 149 | 2 / 151 |
| other Total, other adverse events | 134 / 149 | 146 / 151 |
| serious Total, serious adverse events | 18 / 149 | 25 / 151 |
Outcome results
Primary
Rate of Clinically Significant Exacerbations of Asthma
Clinically significant exacerbation is defined as worsening of asthma which requires use of systemic corticosteroids and/or hospitalizations and/or Emergency Department (ED) visits. Analysis of the number of exacerbations was performed using a negative binomial model with covariates of treatment group, baseline maintenance Oral Corticosteroids (OCS) therapy (OCS vs. no OCS), region, exacerbations in the year prior to the study (as an ordinal variable) and baseline % predicted Forced Expiratory Volume in 1 second (FEV1), and with logarithm of time on treatment as an offset variable.
Time frame: Up to Week 52
Population: The analysis was performed on the Modified Intent-to-Treat (MITT) Set that included all randomized participants who received at least one dose of trial medication. 'Modified' implies that participants who were randomized but did not receive study treatment were excluded.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Mepolizumab 100mg | Rate of Clinically Significant Exacerbations of Asthma | 0.45 Exacerbations per year |
| Placebo | Rate of Clinically Significant Exacerbations of Asthma | 1.31 Exacerbations per year |
Bayesian Dynamic Borrowing
p-value: <0.00195% CI: [0.24, 0.5]Negative binomial model
Secondary
Change From Baseline in Alanine Aminotransferase and Aspartate Aminotransferase
Blood samples was collected for the assessment of change from baseline in clinical parameter Alanine Aminotransferase, Aspartate Aminotransferase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.
Time frame: Baseline and Week 52
Population: The analysis was performed on the MITT Set that included all randomized participants who received at least one dose of trial medication. 'Modified' implies that participants who were randomized but did not receive study treatment were excluded. Number of participants analyzed signifies those participants who were evaluable for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Mepolizumab 100mg | Change From Baseline in Alanine Aminotransferase and Aspartate Aminotransferase | Alanine Aminotransferase | 0.8 Units per liter (U/L) | Standard Deviation 11.49 |
| Mepolizumab 100mg | Change From Baseline in Alanine Aminotransferase and Aspartate Aminotransferase | Aspartate Aminotransferase | 1.5 Units per liter (U/L) | Standard Deviation 7.38 |
| Placebo | Change From Baseline in Alanine Aminotransferase and Aspartate Aminotransferase | Alanine Aminotransferase | 0.0 Units per liter (U/L) | Standard Deviation 10.77 |
| Placebo | Change From Baseline in Alanine Aminotransferase and Aspartate Aminotransferase | Aspartate Aminotransferase | -0.1 Units per liter (U/L) | Standard Deviation 6.31 |
Secondary
Change From Baseline in Albumin and Total Protein
Blood samples was collected for the assessment of change from baseline in clinical parameter albumin, total protein. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.
Time frame: Baseline and Week 52
Population: The analysis was performed on the MITT Set that included all randomized participants who received at least one dose of trial medication. 'Modified' implies that participants who were randomized but did not receive study treatment were excluded. Number of participants analyzed signifies those participants who were evaluable for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Mepolizumab 100mg | Change From Baseline in Albumin and Total Protein | Total Protein | -0.6 Gram per liter (g/L) | Standard Deviation 3.53 |
| Mepolizumab 100mg | Change From Baseline in Albumin and Total Protein | Albumin | 0.1 Gram per liter (g/L) | Standard Deviation 2.55 |
| Placebo | Change From Baseline in Albumin and Total Protein | Albumin | -0.4 Gram per liter (g/L) | Standard Deviation 2.39 |
| Placebo | Change From Baseline in Albumin and Total Protein | Total Protein | -0.6 Gram per liter (g/L) | Standard Deviation 3.7 |
Secondary
Change From Baseline in Alkaline Phosphatase
Blood samples was collected for the assessment of change from baseline in clinical parameter Alkaline Phosphatase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.
Time frame: Baseline and Week 52
Population: The analysis was performed on the MITT Set that included all randomized participants who received at least one dose of trial medication. 'Modified' implies that participants who were randomized but did not receive study treatment were excluded. Number of participants analyzed signifies those participants who were evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Mepolizumab 100mg | Change From Baseline in Alkaline Phosphatase | 2.8 International Unit per Liter (IU/L) | Standard Deviation 16.16 |
| Placebo | Change From Baseline in Alkaline Phosphatase | 1.5 International Unit per Liter (IU/L) | Standard Deviation 12.79 |
Secondary
Change From Baseline in Clinical Chemistry Parameters
Blood samples was collected for the assessment of change from baseline in clinical parameter including total and direct bilirubin, creatinine, glucose, calcium, sodium, potassium, urea. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.
Time frame: Baseline and Week 52
Population: The analysis was performed on the MITT Set that included all randomized participants who received at least one dose of trial medication. 'Modified' implies that participants who were randomized but did not receive study treatment were excluded. Number of participants analyzed signifies those participants who were evaluable for this outcome measure. Here 'number analyzed' signifies those participants who were evaluated at specified category.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Mepolizumab 100mg | Change From Baseline in Clinical Chemistry Parameters | Urea | 0.205 Micro moles per liter (umol/L) | Standard Deviation 1.3284 |
| Mepolizumab 100mg | Change From Baseline in Clinical Chemistry Parameters | Direct Bilirubin | 0.4 Micro moles per liter (umol/L) | Standard Deviation 0.55 |
| Mepolizumab 100mg | Change From Baseline in Clinical Chemistry Parameters | Potassium | 0.00 Micro moles per liter (umol/L) | Standard Deviation 0.35 |
| Mepolizumab 100mg | Change From Baseline in Clinical Chemistry Parameters | Sodium | -0.8 Micro moles per liter (umol/L) | Standard Deviation 2.42 |
| Mepolizumab 100mg | Change From Baseline in Clinical Chemistry Parameters | Calcium | 0.014 Micro moles per liter (umol/L) | Standard Deviation 0.0874 |
| Mepolizumab 100mg | Change From Baseline in Clinical Chemistry Parameters | Creatinine | -0.7 Micro moles per liter (umol/L) | Standard Deviation 6.89 |
| Mepolizumab 100mg | Change From Baseline in Clinical Chemistry Parameters | Glucose | 0.16 Micro moles per liter (umol/L) | Standard Deviation 0.921 |
| Mepolizumab 100mg | Change From Baseline in Clinical Chemistry Parameters | Total Bilirubin | -0.1 Micro moles per liter (umol/L) | Standard Deviation 3.47 |
| Placebo | Change From Baseline in Clinical Chemistry Parameters | Sodium | -0.7 Micro moles per liter (umol/L) | Standard Deviation 2.39 |
| Placebo | Change From Baseline in Clinical Chemistry Parameters | Calcium | 0.016 Micro moles per liter (umol/L) | Standard Deviation 0.0773 |
| Placebo | Change From Baseline in Clinical Chemistry Parameters | Direct Bilirubin | 0.3 Micro moles per liter (umol/L) | Standard Deviation 0.6 |
| Placebo | Change From Baseline in Clinical Chemistry Parameters | Glucose | 0.09 Micro moles per liter (umol/L) | Standard Deviation 1.448 |
| Placebo | Change From Baseline in Clinical Chemistry Parameters | Potassium | -0.04 Micro moles per liter (umol/L) | Standard Deviation 0.328 |
| Placebo | Change From Baseline in Clinical Chemistry Parameters | Creatinine | -0.9 Micro moles per liter (umol/L) | Standard Deviation 6.55 |
| Placebo | Change From Baseline in Clinical Chemistry Parameters | Urea | -0.058 Micro moles per liter (umol/L) | Standard Deviation 1.2335 |
| Placebo | Change From Baseline in Clinical Chemistry Parameters | Total Bilirubin | -0.7 Micro moles per liter (umol/L) | Standard Deviation 3.43 |
Secondary
Change From Baseline in Erythrocytes Count
Blood samples was collected for the assessment of change from baseline in hematology parameter Erythrocytes count. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.
Time frame: Baseline and Week 52
Population: The analysis was performed on the MITT Set that included all randomized participants who received at least one dose of trial medication. 'Modified' implies that participants who were randomized but did not receive study treatment were excluded. Number of participants analyzed signifies those participants who were evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Mepolizumab 100mg | Change From Baseline in Erythrocytes Count | -0.03 Tera cells per liter (10^12/L) | Standard Deviation 0.257 |
| Placebo | Change From Baseline in Erythrocytes Count | -0.05 Tera cells per liter (10^12/L) | Standard Deviation 0.257 |
Secondary
Change From Baseline in Hematocrit
Blood samples was collected for the assessment of change from baseline in hematology parameter Hematocrit. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.
Time frame: Baseline and Week 52
Population: The analysis was performed on the MITT Set that included all randomized participants who received at least one dose of trial medication. 'Modified' implies that participants who were randomized but did not receive study treatment were excluded. Number of participants analyzed signifies those participants who were evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Mepolizumab 100mg | Change From Baseline in Hematocrit | -0.004 Fraction of 1 | Standard Deviation 0.0257 |
| Placebo | Change From Baseline in Hematocrit | -0.003 Fraction of 1 | Standard Deviation 0.026 |
Secondary
Change From Baseline in Platelets Count
Blood samples was collected for the assessment of change from baseline in hematology parameter Platelets count. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the post dose visit value from the Baseline value.
Time frame: Baseline and Week 52
Population: The analysis was performed on the MITT Set that included all randomized participants who received at least one dose of trial medication. 'Modified' implies that participants who were randomized but did not receive study treatment were excluded. Number of participants analyzed signifies those participants who were evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Mepolizumab 100mg | Change From Baseline in Platelets Count | 0.6 Giga cells per liter (10^9/L) | Standard Deviation 35.46 |
| Placebo | Change From Baseline in Platelets Count | -3.5 Giga cells per liter (10^9/L) | Standard Deviation 45.09 |
Secondary
Mean Change From Baseline in Clinic Prebronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 52
FEV1 is the volume of air that can be forced out in one second after taking a deep breath. Prebronchodilator FEV1 were measured via spirometer at Baseline and Week 52. Analysis was performed using mixed model repeated measures with covariates of baseline, baseline maintenance OCS therapy (OCS vs. no OCS), exacerbations in the year prior to the study (as an ordinal variable), treatment and visit, plus interaction terms for visit by baseline and visit by treatment group.
Time frame: Baseline and Week 52
Population: The analysis was performed on the MITT Set that included all randomized participants who received at least one dose of trial medication. 'Modified' implies that participants who were randomized but did not receive study treatment were excluded. Number of participants analyzed signifies those participants who were evaluable for this outcome measure.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Mepolizumab 100mg | Mean Change From Baseline in Clinic Prebronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 52 | 262.79 Milliliter (mL) | Standard Error 34.341 |
| Placebo | Mean Change From Baseline in Clinic Prebronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 52 | 125.67 Milliliter (mL) | Standard Error 35.488 |
Secondary
Mean Change From Baseline in Pulse Rate
Pulse rate measurement were measured in a sitting position after 5 minutes rest.
Time frame: Baseline and Week 52
Population: The analysis was performed on the MITT Set that included all randomized participants who received at least one dose of trial medication. 'Modified' implies that participants who were randomized but did not receive study treatment were excluded. Number of participants analyzed signifies those participants who were evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Mepolizumab 100mg | Mean Change From Baseline in Pulse Rate | -1.3 Beats per minute (bpm) | Standard Deviation 9.71 |
| Placebo | Mean Change From Baseline in Pulse Rate | -1.1 Beats per minute (bpm) | Standard Deviation 10.14 |
Secondary
Mean Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) at Week 52
The SGRQ Questionnaire is a well-established, self-completed tool, with 50 questions comprising three domains: Symptoms, Activity, and Impacts scores (each ranging from 0 to 100; where higher score indicates worst outcome). SGRQ total score was calculated by summing weights from all positive items, divided by sum of weights for all items in SGRQ questionnaire and multiplying by 100. The SGRQ total score ranges from 0 to 100, with 0 implying the best possible health status and 100 implying worst possible health status. Analysis was performed using mixed model repeated measures with covariates of baseline, baseline maintenance OCS therapy (OCS vs. no OCS), exacerbations in the year prior to the study (as an ordinal variable), baseline % predicted FEV1, treatment and visit, plus interaction terms for visit by baseline and visit by treatment group.
Time frame: Baseline and Week 52
Population: The analysis was performed on the MITT Set that included all randomized participants who received at least one dose of trial medication. 'Modified' implies that participants who were randomized but did not receive study treatment were excluded. Number of participants analyzed signifies those participants who were evaluable for this outcome measure.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Mepolizumab 100mg | Mean Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) at Week 52 | -14.29 Scores on a scale | Standard Error 1.526 |
| Placebo | Mean Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) at Week 52 | -7.20 Scores on a scale | Standard Error 1.577 |
Secondary
Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
SBP and DBP were measured in a sitting position after 5 minutes rest. The normal range for SBP is 90-140 mmHg and DBP is 60-90 millimeters of mercury (mmHg).
Time frame: Baseline and Week 52
Population: The analysis was performed on the MITT Set that included all randomized participants who received at least one dose of trial medication. 'Modified' implies that participants who were randomized but did not receive study treatment were excluded. Number of participants analyzed signifies those participants who were evaluable for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Mepolizumab 100mg | Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | Diastolic Blood Pressure, Week 52 | -0.9 Millimeters of mercury (mmHg) | Standard Deviation 9.58 |
| Mepolizumab 100mg | Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | Systolic Blood Pressure, Week 52 | -1.3 Millimeters of mercury (mmHg) | Standard Deviation 12.46 |
| Placebo | Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | Diastolic Blood Pressure, Week 52 | -1.1 Millimeters of mercury (mmHg) | Standard Deviation 8.42 |
| Placebo | Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) | Systolic Blood Pressure, Week 52 | -0.5 Millimeters of mercury (mmHg) | Standard Deviation 10.75 |
Secondary
Number of Participants With Adverse Events (AEs) Including Systemic (i.e., Allergic [Type I Hypersensitivity] and Other Systemic) and Injection Site Reactions
AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Systemic reactions and local injection site reactions are adverse events of special interest (AESIs).
Time frame: Up to Week 52
Population: The analysis was performed on the MITT Set that included all randomized participants who received at least one dose of trial medication. 'Modified' implies that participants who were randomized but did not receive study treatment were excluded.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Mepolizumab 100mg | Number of Participants With Adverse Events (AEs) Including Systemic (i.e., Allergic [Type I Hypersensitivity] and Other Systemic) and Injection Site Reactions | Participants with Systemic Reactions | 4 Participants |
| Mepolizumab 100mg | Number of Participants With Adverse Events (AEs) Including Systemic (i.e., Allergic [Type I Hypersensitivity] and Other Systemic) and Injection Site Reactions | Participants with AE | 135 Participants |
| Mepolizumab 100mg | Number of Participants With Adverse Events (AEs) Including Systemic (i.e., Allergic [Type I Hypersensitivity] and Other Systemic) and Injection Site Reactions | Participants with Local Injection Site Reactions | 3 Participants |
| Placebo | Number of Participants With Adverse Events (AEs) Including Systemic (i.e., Allergic [Type I Hypersensitivity] and Other Systemic) and Injection Site Reactions | Participants with AE | 146 Participants |
| Placebo | Number of Participants With Adverse Events (AEs) Including Systemic (i.e., Allergic [Type I Hypersensitivity] and Other Systemic) and Injection Site Reactions | Participants with Systemic Reactions | 2 Participants |
| Placebo | Number of Participants With Adverse Events (AEs) Including Systemic (i.e., Allergic [Type I Hypersensitivity] and Other Systemic) and Injection Site Reactions | Participants with Local Injection Site Reactions | 2 Participants |
Secondary
Number of Participants With Clinically Significant Abnormal 12-Lead Electrocardiogram (ECG) Findings
12-Lead electrocardiogram (ECG) measurements were obtained after the participants had rested in the supine position for 5 minutes. Clinically significant abnormal findings are based on the judgement of the investigator.
Time frame: Up to Week 52
Population: The analysis was performed on the MITT Set that included all randomized participants who received at least one dose of trial medication. 'Modified' implies that participants who were randomized but did not receive study treatment were excluded. Number of participants analyzed signifies those participants who were evaluable for this outcome measure.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Mepolizumab 100mg | Number of Participants With Clinically Significant Abnormal 12-Lead Electrocardiogram (ECG) Findings | 7 Participants |
| Placebo | Number of Participants With Clinically Significant Abnormal 12-Lead Electrocardiogram (ECG) Findings | 13 Participants |
Secondary
Number of Participants With Clinically Significant Exacerbations Requiring Hospitalization
An exacerbation is defined as worsening of asthma requiring the use of systemic corticosteroids and/or emergency department visit, or hospitalization. Analysis of number of exacerbations was performed using a negative binomial model with covariates of treatment group, baseline maintenance OCS therapy (OCS vs. no OCS), exacerbations in the year prior to the study (as an ordinal variable) and baseline % predicted FEV1, and with logarithm of time on treatment as an offset variable. The summary data for participants with 0, 1, 2 and 3 exacerbations requiring hospitalization are summarized.
Time frame: Up to Week 52
Population: The analysis was performed on the MITT Set that included all randomized participants who received at least one dose of trial medication. 'Modified' implies that participants who were randomized but did not receive study treatment were excluded.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Mepolizumab 100mg | Number of Participants With Clinically Significant Exacerbations Requiring Hospitalization | 3 exacerbations | 0 Participants |
| Mepolizumab 100mg | Number of Participants With Clinically Significant Exacerbations Requiring Hospitalization | 0 exacerbation | 145 Participants |
| Mepolizumab 100mg | Number of Participants With Clinically Significant Exacerbations Requiring Hospitalization | 1 exacerbation | 3 Participants |
| Mepolizumab 100mg | Number of Participants With Clinically Significant Exacerbations Requiring Hospitalization | 2 exacerbations | 1 Participants |
| Placebo | Number of Participants With Clinically Significant Exacerbations Requiring Hospitalization | 2 exacerbations | 1 Participants |
| Placebo | Number of Participants With Clinically Significant Exacerbations Requiring Hospitalization | 3 exacerbations | 1 Participants |
| Placebo | Number of Participants With Clinically Significant Exacerbations Requiring Hospitalization | 1 exacerbation | 10 Participants |
| Placebo | Number of Participants With Clinically Significant Exacerbations Requiring Hospitalization | 0 exacerbation | 139 Participants |
Secondary
Number of Participants With Clinically Significant Exacerbations Requiring Hospitalization (Including Intubation and Admittance to an Intensive Care Unit [ICU]) or Emergency Department (ED) Visits
An exacerbation is defined as worsening of asthma requiring the use of systemic corticosteroids and/or emergency department visit, or hospitalization. The number of exacerbations requiring hospitalization including incubation and admittance to an Intensive care unit (ICU) or ED visits were evaluated. Analysis of number of exacerbations was performed using a negative binomial model with covariates of treatment group, baseline maintenance OCS therapy (OCS vs. no OCS), exacerbations in the year prior to the study (as an ordinal variable) and baseline % predicted FEV1, and with logarithm of time on treatment as an offset variable. The data for participants with 0, 1, 2 and 3 exacerbations requiring hospitalization (including intubation and admittance to an ICU) or ED visits are summarized.
Time frame: Up to Week 52
Population: The analysis was performed on the MITT Set that included all randomized participants who received at least one dose of trial medication. 'Modified' implies that participants who were randomized but did not receive study treatment were excluded.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Mepolizumab 100mg | Number of Participants With Clinically Significant Exacerbations Requiring Hospitalization (Including Intubation and Admittance to an Intensive Care Unit [ICU]) or Emergency Department (ED) Visits | 0 exacerbation | 144 Participants |
| Mepolizumab 100mg | Number of Participants With Clinically Significant Exacerbations Requiring Hospitalization (Including Intubation and Admittance to an Intensive Care Unit [ICU]) or Emergency Department (ED) Visits | 2 exacerbations | 2 Participants |
| Mepolizumab 100mg | Number of Participants With Clinically Significant Exacerbations Requiring Hospitalization (Including Intubation and Admittance to an Intensive Care Unit [ICU]) or Emergency Department (ED) Visits | 3 exacerbations | 0 Participants |
| Mepolizumab 100mg | Number of Participants With Clinically Significant Exacerbations Requiring Hospitalization (Including Intubation and Admittance to an Intensive Care Unit [ICU]) or Emergency Department (ED) Visits | 1 exacerbation | 3 Participants |
| Placebo | Number of Participants With Clinically Significant Exacerbations Requiring Hospitalization (Including Intubation and Admittance to an Intensive Care Unit [ICU]) or Emergency Department (ED) Visits | 3 exacerbations | 1 Participants |
| Placebo | Number of Participants With Clinically Significant Exacerbations Requiring Hospitalization (Including Intubation and Admittance to an Intensive Care Unit [ICU]) or Emergency Department (ED) Visits | 2 exacerbations | 3 Participants |
| Placebo | Number of Participants With Clinically Significant Exacerbations Requiring Hospitalization (Including Intubation and Admittance to an Intensive Care Unit [ICU]) or Emergency Department (ED) Visits | 1 exacerbation | 14 Participants |
| Placebo | Number of Participants With Clinically Significant Exacerbations Requiring Hospitalization (Including Intubation and Admittance to an Intensive Care Unit [ICU]) or Emergency Department (ED) Visits | 0 exacerbation | 133 Participants |
Secondary
Number of Participants With Positive Anti-Mepolizumab Antibody
Blood samples were collected for detection of binding and neutralizing anti-mepolizumab antibodies. Samples with a positive screening result continued for confirmation analysis. Samples with a positive confirmation analysis were considered positive for mepolizumab Anti-drug antibody (ADA).
Time frame: Up to Week 52
Population: The analysis was performed on the MITT Set that included all randomized participants who received at least one dose of trial medication. 'Modified' implies that participants who were randomized but did not receive study treatment were excluded.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Mepolizumab 100mg | Number of Participants With Positive Anti-Mepolizumab Antibody | 5 Participants |
| Placebo | Number of Participants With Positive Anti-Mepolizumab Antibody | 0 Participants |
Secondary
Percent Change From Baseline in Mean White Blood Cell (WBC) Count With Differential (Neutrophils, Lymphocytes, Monocytes. Eosinophils and Basophils)
Blood samples was collected for the assessment of change from baseline in WBC) count with differential (neutrophils, lymphocytes, monocytes. eosinophils and basophils). Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline and Week 52
Population: The analysis was performed on the MITT Set that included all randomized participants who received at least one dose of trial medication. 'Modified' implies that participants who were randomized but did not receive study treatment were excluded. Number of participants analyzed signifies those participants who were evaluable for this outcome measure.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Mepolizumab 100mg | Percent Change From Baseline in Mean White Blood Cell (WBC) Count With Differential (Neutrophils, Lymphocytes, Monocytes. Eosinophils and Basophils) | Eosinophils/Leukocytes | -4.95 Percent change |
| Mepolizumab 100mg | Percent Change From Baseline in Mean White Blood Cell (WBC) Count With Differential (Neutrophils, Lymphocytes, Monocytes. Eosinophils and Basophils) | Lymphocytes/Leukocytes | 0.45 Percent change |
| Mepolizumab 100mg | Percent Change From Baseline in Mean White Blood Cell (WBC) Count With Differential (Neutrophils, Lymphocytes, Monocytes. Eosinophils and Basophils) | Monocytes/Leukocytes | 0.30 Percent change |
| Mepolizumab 100mg | Percent Change From Baseline in Mean White Blood Cell (WBC) Count With Differential (Neutrophils, Lymphocytes, Monocytes. Eosinophils and Basophils) | Neutrophils/Leukocytes | 4.65 Percent change |
| Mepolizumab 100mg | Percent Change From Baseline in Mean White Blood Cell (WBC) Count With Differential (Neutrophils, Lymphocytes, Monocytes. Eosinophils and Basophils) | Basophils/Leukocytes | 0.00 Percent change |
| Placebo | Percent Change From Baseline in Mean White Blood Cell (WBC) Count With Differential (Neutrophils, Lymphocytes, Monocytes. Eosinophils and Basophils) | Neutrophils/Leukocytes | -0.50 Percent change |
| Placebo | Percent Change From Baseline in Mean White Blood Cell (WBC) Count With Differential (Neutrophils, Lymphocytes, Monocytes. Eosinophils and Basophils) | Eosinophils/Leukocytes | -0.80 Percent change |
| Placebo | Percent Change From Baseline in Mean White Blood Cell (WBC) Count With Differential (Neutrophils, Lymphocytes, Monocytes. Eosinophils and Basophils) | Basophils/Leukocytes | 0.20 Percent change |
| Placebo | Percent Change From Baseline in Mean White Blood Cell (WBC) Count With Differential (Neutrophils, Lymphocytes, Monocytes. Eosinophils and Basophils) | Lymphocytes/Leukocytes | 0.20 Percent change |
| Placebo | Percent Change From Baseline in Mean White Blood Cell (WBC) Count With Differential (Neutrophils, Lymphocytes, Monocytes. Eosinophils and Basophils) | Monocytes/Leukocytes | 0.30 Percent change |
Secondary
Percent Probability of First Clinically Significant Exacerbations at Week 16, Week 32, and Week 52
Clinically significant exacerbation is defined as worsening of asthma which requires use of systemic corticosteroids and/or hospitalizations and/or Emergency Department (ED) visits. Analysis of the number of exacerbations was performed using a negative binomial model with covariates of treatment group, baseline maintenance Oral Corticosteroids (OCS) therapy (OCS vs. no OCS), region, exacerbations in the year prior to the study (as an ordinal variable) and baseline % predicted Forced Expiratory Volume in 1 second (FEV1), and with logarithm of time on treatment as an offset variable. Time to first clinically significant exacerbation was analyzed using Kaplan-Meier estimates and expressed in terms of probability.
Time frame: Week 16, 32 and 52
Population: The analysis was performed on the MITT Set that included all randomized participants who received at least one dose of trial medication. 'Modified' implies that participants who were randomized but did not receive study treatment were excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Mepolizumab 100mg | Percent Probability of First Clinically Significant Exacerbations at Week 16, Week 32, and Week 52 | Week 16 | 14.1 Percent probability |
| Mepolizumab 100mg | Percent Probability of First Clinically Significant Exacerbations at Week 16, Week 32, and Week 52 | Week 52 | 28.4 Percent probability |
| Mepolizumab 100mg | Percent Probability of First Clinically Significant Exacerbations at Week 16, Week 32, and Week 52 | Week 32 | 18.1 Percent probability |
| Placebo | Percent Probability of First Clinically Significant Exacerbations at Week 16, Week 32, and Week 52 | Week 52 | 53.6 Percent probability |
| Placebo | Percent Probability of First Clinically Significant Exacerbations at Week 16, Week 32, and Week 52 | Week 16 | 34.7 Percent probability |
| Placebo | Percent Probability of First Clinically Significant Exacerbations at Week 16, Week 32, and Week 52 | Week 32 | 47.9 Percent probability |